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PrognosisAbstract Introduction: Conservative active surveillance has been proposed for low-risk
papillary thyroid microcarcinoma (PTMC), defined as 1.0 cm and lacking clinical aggressive
features, but controversy exists with accepting it as not all such PTMCs are uniformly destined
for benign prognosis. This study investigated whether BRAF V600E status could further risk
stratify PTMC, particularly low-risk PTMC, and can thus help with more accurate case selec-
tion for conservative management.
Methods: This international multicenter study included 743 patients treated with total thyroid-
ectomy for PTMC (584 women and 159 men), with a median age of 49 years (interquartile
range [IQR], 39e59 years) and a median follow-up time of 53 months (IQR, 25e93 months).
Results: On overall analyses of all PTMCs, tumour recurrences were 6.4% (32/502) versus
10.8% (26/241) in BRAF mutation-negative versus BRAF mutation-positive patients (P
Z 0.041), with a hazard ratio (HR) of 2.44 (95% CI (confidence interval), 1.15e5.20) after
multivariate adjustment for confounding clinical factors. On the analyses of low-risk PTMC,
recurrences were 1.3% (5/383) versus 4.3% (6/139) in BRAF mutation-negative versus BRAF
mutation-positive patients, with an HR of 6.65 (95% CI, 1.80e24.65) after adjustment for con-
founding clinical factors. BRAF mutation was associated with a significant decline in the
KaplaneMeier recurrence-free survival curve in low-risk PTMC.
Conclusions: BRAF V600E differentiates the recurrence risk of PTMC, particularly low-risk
PTMC. Given the robust negative predictive value, conservative active surveillance of BRAF
mutation-negative low-risk PTMC is reasonable whereas the increased recurrence risk and
other well-known adverse effects of BRAF V600E make the feasibility of long-term conserva-
tive surveillance uncertain for BRAF mutation-positive PTMC.
ª 2019 Elsevier Ltd. All rights reserved.1. Introduction
Papillary thyroid cancer (PTC) is a common endocrine
malignancy with a rapidly rising incidence globally in
recent decades [1e4]. Papillary thyroid microcarcinoma
(PTMC), defined as tumour 1.0 cm in its greatest
dimension [5], constitutes a major portion of thyroid
cancer, close to 50% of all thyroid malignancies in some
studies [1,6,7]. The Surveillance, Epidemiology, and End
Results (SEER) data have shown an increase in the
incidence of PTMC from 3.39 per 100,000 person-years
in 1983e1985 to 13.02 per 100,000 person-years in
2010e2013, with an average annual percent change of
9.3% [1]. Although the majority of patients with PTMC
have an indolent disease course with no serious clinical
outcomes, some patients do have tumour metastasis and
even disease-specific mortality [8e10]. Of particular note
is that recurrence of PTMC can occur after treatment,
which may be associated with increased risk of patient
morbidity and mortality. Thus, prevention of disease
recurrence of PTMC is a major goal of its treatment in
the current clinical practice.
It is often difficult to precisely risk stratify and
accordingly treat PTMC to achieve an optimal benefit-
harm balance of the treatments. Therefore, the man-
agement style of PTMC, particularly low-risk PTMC, is
currently widely variable in different clinical practices
around the world, ranging from total thyroidectomy forevery patient with PTMC to non-surgical active sur-
veillance in patients with clinically low-risk PTMC. The
conservative active surveillance is attractive but
controversial as an approach to clinically low-risk
PTMC, defined as lack of extrathyroidal extension
(ETE), lymph node metastasis (LNM) and distant
metastasis (DM), which are well known to be associated
with an increased risk of recurrence [9e11]. One major
issue is that in some patients initially apparently low-risk
PTMC is actually inherently destined, perhaps geneti-
cally driven, for a later course of poor progno-
sisddisease recurrence and even mortality. To identify
those patients with PTMC that has clinically apparently
low-risk at the initial presentation but has inherently
high potential for poor prognosis, such as disease
recurrence, is clinically challenging. The opposite is also
truedi.e., it may not be always straightforward to
identify the cases with apparently low-risk PTMC that is
truly of low risk. A novel approach, such as the use of
genetic guidance, which could further risk stratify clin-
ically apparently low-risk PTMC, could be useful in
helping more precisely to define the management of this
common type of thyroid cancer.
In recent years, BRAF V600E mutation has been
introduced as a genetic prognostic marker to assist the
risk evaluation of PTC [12,13]. There have also been
some studies on PTMC in this regard, but they have
been virtually all focused on the overall analyses of
K.J. Kim et al. / European Journal of Cancer 124 (2020) 161e169 163PTMC with inconsistent results [11,14,17]. There are
limited data on the prognostic value of BRAF V600E in
the unique category of PTCdclinically low-risk PTMC.
More than ten years ago, Mazzaferri suggested that
BRAF V600E could be useful in further risk stratifica-
tion of low-risk PTMC [18], but current clinical guide-
lines on the treatment of thyroid cancer, such as the
American Thyroid Association guidelines, have not
been able to specifically define yet BRAF V600E as a
risk-differentiating factor for low-risk PTMC [19]. This
controversy derives largely from the fact that direct data
on the prognostic value of BRAF V600E in the risk
assessment of low-risk PTMC is lacking. There has been
particularly lack of a large multicenter study that could
provide a strong analysis power to resolve this contro-
versy. In view of this, we conducted the present large
international multicenter study to directly investigate
the prognostic value of BRAF V600E mutation in
PTMC, with a particular emphasis on low-risk PTMC.2. Materials and methods
2.1. Patients and mutational analyses
This study initially included 2638 patients with PTC
from 11 medical centres in six countries, as detailed
previously [20e24]. After exclusion of patients with
tumour size >1.0 cm, we had 743 patients with PTMC
(584 women and 159 men), with a median age of 49
years (interquartile range [IQR], 39e59 years) and a
median clinical follow-up time of 53 months (IQR,
25e93 months) from 1978 to 2015. The clinicopatho-
logical demographic characteristics of the patients with
PTMC in this cohort from different medical centres are
presented in Supplemental Table S1. We defined low-
risk PTMC as having no ETE, LNM, and DM and
high-risk PTMC as having at least one of these high-risk
characteristics. All patients received total or near-total
thyroidectomy. Neck lymph node dissection and radio-
iodine ablation were pursued when clinically indicated
as previously described [16,22,23]. Tumour recurrence
was defined as combined persistent and recurrent disease
confirmed by histologic/cytologic/radiographic/
biochemical criteria as previously described [16].
Follow-up time was defined as the time from initial
thyroidectomy to tumour recurrence or to the latest
clinical contact in the case of no recurrence. The study
was approved by the institutional review board of all the
centres involved and informed consent was obtained
from patients where required. For BRAF V600E muta-
tion analyses, we amplified exon 15 of the BRAF gene
containing the mutation hotspot using polymerase chain
reaction primers, as described previously [24e35]. Ge-
netic analyses were performed after surgical and radio-
iodine ablation treatments in all patients and the BRAF
mutation status did not affect the treatment strategy.2.2. Statistical analysis
We presented continuous data as medians and
IQRs using the WilcoxoneManneWhitney test for the
analysis of non-normally distributed variables and
presented categorical data as frequencies and percent-
age using a chi-squared test for the analysis or Fisher’s
exact test for small case numbers. KaplaneMeier sur-
vival curves with log-rank test were used to analyse the
recurrence-free survival. Independent risk factors
associated with disease recurrence were examined by
Cox-regression analyses to generate hazard ratio (HR)
and 95% confidence interval (CI). All reported P values
were two-sided and a value <0.05 was considered sig-
nificant. All analyses were performed using SPSS
version 20.0 (IBM SPSS, Inc. New York, NY) and
GraphPad Prism version 7 (GraphPad Software, San
Diego, CA).3. Results
3.1. Effect of BRAF V600E mutation on disease
recurrence of PTMC in the overall cohort
We first took the advantage of this large multicenter
cohort of 743 patients with PTMC to examine the
general effect of BRAF V600E mutation on tumour
behaviours, particularly disease recurrence, in the
overall PTMC cohort (Table 1). The overall prevalence
of BRAF V600E mutation in PTMC was 32.4% (241/
743). BRAF V600E was associated with several high-risk
tumour behaviours, such as ETE and LNM. The tumor
recurrence rate in patients with BRAF mutation-
negative PTMC was significantly lower compared with
that of BRAF mutation-positive patients (6.4%
versus 10.8%, respectively), with an unadjusted HR of
2.01 (95% CI, 1.20e3.38), which remained significant at
2.44 (95% CI, 1.15e5.20) after adjustment for patient
age, sex, conventional pathological risk factors, medical
centre, and radioactive iodine treatment (Table 2). A
significant association between BRAF V600E mutation
and decreased recurrence-free survival is also revealed
on KaplaneMeier analysis (log-rank P Z 0.007;
Fig. 1A).
Similar results were obtained when the analyses were
performed only on a conventional variant of PTMC
(CPTMC). The prevalence of BRAF mutation in this
group was 32.9% (198/602). Tumour recurrence rates in
CPTMC were 6.2% (25/404) versus 12.1% (24/198) in
BRAF mutation-negative and BRAF mutation-positive
patients, respectively, with an HR of 2.94 (95% CI,
1.20e7.20) after adjustment for patient age, sex, con-
ventional pathological risk factors, medical centre, and
radioactive iodine treatment (Table 2). On
KaplaneMeier analysis, the recurrence-free survival
curve of BRAF mutation-positive patients significantly
Table 2
Hazard ratios of BRAF V600E mutation for recurrence of PTMC on the overall analysis.
Recurrence n (%) Unadjusted Adjusteda
HR (95% CI) P-value HR (95% CI) P-value
All PTMCs
BRAF V600E negative 32/502 (6.4) 1 (reference) 1 (reference)
BRAF V600E positive 26/241 (10.8) 2.01 (1.20e3.38) 0.008 2.44 (1.15e5.20) 0.020
Conventional PTMC
BRAF V600E negative 25/404 (6.2) 1 (reference) 1 (reference)
BRAF V600E positive 24/198 (12.1) 2.29 (1.30e4.01) 0.004 2.94 (1.20e7.20) 0.018
PTMC, papillary thyroid microcarcinoma; CI, confidential interval.
a Adjusted for patient age at diagnosis, sex, tumour size, cervical lymph node metastasis, extrathyroidal extension, vascular invasion, multi-
focality, medical centres, and radioactive iodine treatments.
Table 1
Clinicopathological demographic characteristics of papillary thyroid microcarcinoma in patients according to the BRAF genotype.
All patients BRAF V600E negative BRAF V600E positive P-value
Total case, n (%) 743 502 (67.6) 241 (32.4)
Age, median (interquartile range (IQR)) 49 (39e59) 48 (39e59) 49 (39e59) 0.706
Female, n (%) 584 (78.6) 392 (78.1) 192 (79.7) 0.623
Tumour size, median (IQR), cm 0.8 (0.5e1.0) 0.7 (0.5e1.0) 0.8 (0.6e1.0) <0.001
Extrathyroidal extension, n (%) 98 (13.2) 44 (8.8) 54 (22.4) <0.001
Lymph node metastasis, n (%) 168 (22.6) 95 (18.9) 73 (30.3) 0.001
Vascular invasion, n (%) 16/319 (5.0) 11/257 (4.3) 5/62 (8.1) 0.209
Multifocality, n (%) 281 (37.8) 172 (34.3) 109 (45.2) 0.004
Distant metastasis, n (%) 11 (1.5) 7 (1.4) 4 (1.7) 0.754
Stage (AJCC 8th), n (%), (n Z 732)
I 691 (93) 474 (95.4) 217 (92.3) 0.173
II 38 (5.1) 21 (4.2) 17 (7.2)
III 0 0 0
IV 3 (0.4) 2 (0.4) 1 (0.4)
131I treatment, n (%) 447/742 (60.2) 257/501 (51.3) 190/241 (78.8) <0.001
131I dose, median (IQR), mCi 50 (0e100) 30 (0e100) 100 (30e101) <0.001
Follow time, median (IQR), months 53 (25e93) 56 (29.5e99) 40 (21e83) <0.001
Tumour recurrence, n (%) 58 (7.8) 32 (6.4) 26 (10.8) 0.041
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negative patients (log-rank P Z 0.003; Fig. 1B).
3.2. Effect of BRAF V600E mutation on disease
recurrence of low- and high-risk PTMCs
We next examined the effect of BRAF V600E mutation
on disease recurrence of PTMC in different risk groups.
As shown in Table 3, the overall BRAF V600E rate was
26.6% (139/522) and disease recurrence rate was 2.1%
(11/522) in low-risk PTMC. The recurrence rates were
1.3% versus 4.3% in BRAF mutation-negative versus
BRAF mutation-positive patients, respectively, with a
HR of 6.65 (95% CI, 1.80e24.65) after adjustment for
patient age, sex, medical centre, and radioactive iodine
treatment. The negative predictive value of BRAF mu-
tation for recurrence of low-risk PTMC was 98.7% (95%
CI, 96.8%e99.5%) (Table 3). In the high-risk group,
however, BRAF mutation had no significant effect on
tumour recurrence, with a HR of 1.28 (95% CI,
0.69e2.37) after adjustment for patient age, sex, medical
centre, and radioactive iodine treatment. On
KaplaneMeier analysis, BRAF mutation was associatedwith a significant decrease in recurrence-free survival
curve in low-risk PTMC (log-rank PZ 0.023; Fig. 2A),
whereas in the high-risk group, BRAF mutation had no
significant effect on the recurrence-free survival curve
(log-rank P Z 0.688; Fig. 2B).
Similar results were obtained in CPTMC. The
recurrence rate in low-risk CPTMC was 1.3% versus
4.3% in BRAF mutation-negative versus BRAF muta-
tion-positive patients, with a HR of 5.15 (95% CI, 1.21
to 21.83) after adjustment for patients age, sex, medical
centre, and radioactive iodine treatment (Table 3). In
high-risk CPTMC, BRAF mutation had no effect on
tumour recurrence, with an adjusted HR of 1.34 (95%
CI, 0.71 to 2.56). On KaplaneMeier analyses, BRAF
mutation was associated with a significant decline in the
recurrence-free survival curve in low-risk CPTMC (log-
rank P Z 0.036; Fig. 2C), but not in high-risk CPTMC
(log-rank P Z 0.422; Fig. 2D).
4. Discussion
It can be a challenging task to precisely risk stratify
patients with PTMC for prognostic risk level-based
Fig. 1. KaplaneMeier analysis of disease recurrence-free survival by BRAF V600E mutation status in papillary thyroid microcarcinoma
(PTMC). A. All types of PTMC. B. Conventional variant of PTMC. Comparison of recurrence-free survival was performed between
BRAF V600E mutation-positive and wild-type BRAF patients using the log-rank test. Follow-up time is truncated at 10 years.
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risk cases. Although patients with PTMC generally have
an excellent prognosis [36,37], some patients experience
tumour recurrence and even mortality [9,10], suggesting
that all PTMCs do not have the same intrinsic risk for
poor outcomes. There are currently ongoing debates
particularly on how to further risk stratify and appro-
priately manage clinically apparently low-risk PTMC.
Controversies exist particularly on how to select cases of
such low-risk PTMC for conservative active
surveillance.
In this context, the present large international
multicenter study has demonstrated that BRAF V600E
mutation can be a prognostic marker for poorer clini-
copathological outcomes of PTMC, particularly for
disease recurrence of low-risk PTMC. In fact, this study
has for the first time shown that BRAF mutation can
further differentiate the recurrence risk of clinically low-
risk PTMCdwild-type BRAF patients have an
extremely low risk of recurrence whereas BRAF muta-
tion patients have a significantly increased recurrence
risk, representing an independent prognostic value of
BRAF mutation in the apparently clinically low-risk
PTMC. Unlike in low-risk PTMC, in high-risk PTMC,
BRAF V600E mutation was not an independent risk
factor for disease recurrence in the present study. This
finding may be expected, given the fact that even in the
absence of BRAF mutation, classical high-risk tumour
features already existed in high-risk PTMC as defined in
the present study, which would be associated with a high
recurrence rate. These findings in the present study by
analysing low- and high-risk PTMCs separately may
now reconcile the inconsistent results of previous studies
on the prognostic value of BRAF V600E in the overall
analyses of all PTMCs as the outcomes of those studies
would vary depending on the compositae portions of
low- and high-risk PTMCs in the cohorts of patients
included [11,14e17].
Active surveillance has been recently proposed as an
alternative option to surgical treatment in low-risk
PTMC, which is drawing increasing attention[19,38,39]. It is of concern, however, that all low-risk
PTMCs may not uniformly remain “silent” without
clinical consequences [40e42]. It is also unknown what
molecular markers can distinguish intrinsically aggres-
sive but initially apparently low-risk PTMC from truly
indolent low-risk PTMC. A striking finding in the pre-
sent study was the extremely low recurrence rate in low-
risk PTMC that harboured the wild-type BRAF, repre-
senting a robust negative predictive value (99%) of
BRAF V600E for disease recurrence. It has been recently
recommended by Miyauchi and Ito that active surveil-
lance is the primary approach to the management of
clinically low-risk PTMC as opposed to immediate
surgical treatment [43]. Our present study suggests that
this conservative approach is reasonable for BRAF
mutation-negative low-risk PTMC given its extremely
low recurrence rate. This is supported also by the fact
that virtually no PTC-related mortality occurred in pa-
tients with BRAF mutation-negative PTC, particularly
in patients with conventional PTC, including even PTC
>1.0 cm [44]. In this context, because the cost of BRAF
test is generally low and the cost of thyroidectomy is
high, this BRAF status-based approach to the manage-
ment of PTMC would spare many patients from total
thyroidectomy or even any thyroidectomy and would
thus likely be cost-saving, in addition to other
advantages.
Our present study demonstrated that BRAF V600E
mutation could independently define a significantly
increased risk of disease recurrence in initially appar-
ently low-risk PTMC. This finding, together with the
well-known other adverse effects of BRAF V600E on
PTC [12,13,16,24], suggests that non-surgical long-term
surveillance may not be appropriate for patients with
BRAF mutation-positive low-risk PTMC. Even a
recurrence rate of 4.3% in the BRAF mutation-positive
low-risk PTMC found in the present study seems to be
relatively low; this significant increase in recurrence risk
compared with BRAF mutation-negative PTMC sug-
gests a significantly increased aggressive potential of the
tumour associated with BRAF V600E. This is a concern
Table 3
Hazard ratios of BRAF V600E mutation for recurrence of PTMC in low- and high-risk groups.
tumour recurrence Unadjusted Adjusteda Negative predictive value, %
(95% CI)
Overall, n
(%)
BRAF V600E
negative, n (%)
BRAF V600E
positive, n (%)
P-
value
HR (95%
CI)
P-
value
HR (95%
CI)
P-
value
All PTMCs
Low-risk
group
11/522
(2.1)
5/383 (1.3) 6/139 (4.3) 0.076 3.63 (1.11
e11.91)
0.033 6.65 (1.80
e24.65)
0.005 98.7 (96.8e99.5)
High-risk
group
47/221
(21.3)
27/119 (22.7) 20/102 (19.6) 0.577 1.13 (0.63
e2.02)
0.689 1.28 (0.69
e2.37)
0.437 77.3 (68.5e84.3)
Conventional PTMC
Low-risk
group
9/423 (2.1) 4/308 (1.3) 5/115 (4.3) 0.066 3.71 (1.00
e13.85)
0.051 5.15 (1.21
e21.83)
0.026 98.7 (96.5e99.6)
High-risk
group
40/179
(22.3)
21/96 (21.9) 19/83 (22.9) 0.871 1.29 (0.69
e2.41)
0.424 1.34 (0.71
e2.56)
0.369 78.1 (68.3e85.7)
PTMC, papillary thyroid microcarcinoma; CI, confidential interval.
a Adjusted for patient age at diagnosis, sex, medical centres, and radioactive iodine treatments.
Fig. 2. KaplaneMeier analysis of disease recurrence-free survival by BRAF V600E mutation status in PTMC of different risks. A. Low-
risk PTMC; B. high-risk PTMC; C. low-risk conventional PTMC; and D. high-risk conventional PTMC. Comparison of recurrence-free
survival was performed between BRAF V600E mutation-positive and wild-type BRAF patients using the log-rank test. Follow-up time
was truncated at 10 years.
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mutation on clinical outcomes of thyroid cancer will
likely be substantial if significant tumour growth, ETE,
or LNM occurs. This is because previous findings sug-
gest that BRAF V600E-positive intrathyroidal PTC
>1.0 cm has a substantially increased recurrence risk,
particularly in the case of tumours >2.0 cm where there
was a robustly increased recurrence risk to around
20e30%, which was comparable with the recurrence risk
of invasive PTC [21]. It has been previouslydemonstrated that BRAF V600E and ETE or LNM has
a robustly synergistic adverse effect on clinical outcomes
of PTC, including disease recurrence [16] and patient
mortality [24]. New ETE and LNM can develop even in
initially low-risk PTMC if given sufficient time and even
in the absence of significant growth of the primary
tumour. Once ETE and LNM occur in BRAF V600E-
positive tumour, synergistic interactive effects between
the newly developed aggressive pathological factors and
BRAF V600E on poor clinical outcomes of PTMC may
K.J. Kim et al. / European Journal of Cancer 124 (2020) 161e169 167intensify [16,24]. Moreover, the adverse effects of BRAF
V600E on clinical outcomes of PTC, such as disease-
specific mortality, start to be significantly manifested
particularly after 10 years of clinical follow-up from the
initial treatment [24]. Therefore, BRAF mutation-
positive low-risk PTMC has an aggressive potential if
left untreated, making uncertain the feasibility of the
long-term non-surgical conservative surveillance for
such BRAF mutation-positive thyroid cancer. It is worth
noting that BRAF mutation was found only in 26.6% of
patients with clinically low-risk PTMC in the present
study. Thus, if the BRAF mutation status is used to
assist the management of low-risk PTMC, the vast
majority of patients could be managed with conservative
surveillance although only a minority of patients need to
pursue thyroidectomy. It has been recently recom-
mended that a clinical risk level-based approach in the
prognostic use of BRAF mutation to the management of
PTC be applied and, as such, thyroid lobectomy may be
just adequate for BRAF mutation-positive low-risk
PTMC [45].
A limitation of the present study was the relatively
small number of patients in the high-risk group of
PTMC, reducing the power to conclude the results.
Previous studies demonstrated that even though BRAF
mutation-negative PTC could have recurrence [16,46],
PTC-related mortality virtually only occurred in pa-
tients with BRAF mutation-positive PTC [44]. Thus, the
BRAF mutation status may also have a prognostic value
even in high-risk PTMC: absence of the mutation im-
plies virtually no PTMC-related mortality. The lack of
information on other mutations, such as rat sarcoma
(RAS) mutations and telomerase reverse transcriptase
(TERT) promoter mutation, is another limitation of this
study. However, RAS mutations are mutually exclusive
with BRAF V600E [47] and they alone do not have
adverse effects on the outcomes of low-risk PTC [45].
TERT promoter mutation is uncommon in PTMC,
which alone is also not associated with aggressiveness of
PTMC [48]. We analysed the Johns Hopkins cases,
which had information on both the BRAF and TERT
mutations, and found that TERT promoter mutation
alone indeed had no effect, whereas BRAF mutation
alone had a significant effect on disease recurrence either
in the overall analysis of all PTMCs or low-risk PTMC;
in fact, a remarkable recurrence rate of 13.5% (5/37) was
observed in the group with BRAF mutation alone versus
only 1.6% (3/189) in the group with no mutation
(Supplemental Table S2). BRAF V600E and TERT
promoter mutations often coexist in PTC to form an
oncogenic genetic duet that is associated with a robustly
increased risk of poor clinical outcomes of PTC [44,46].
The number of cases with this genetic duet was too small
in PTMC, particularly low-risk PTMC, to analyse in the
present study (Supplemental Table S2).
In summary, in this large multicenter study, we
demonstrate that BRAF V600E can further differentiatethe prognostic risk of low-risk PTMC: the mutation has
an extremely robust negative predictive value for disease
recurrence and is associated with a significantly
increased recurrence. These results, together with the
known aggressive role of BRAF V600E in PTC in gen-
eral, suggest that BRAF mutation-positive PTMC can
be reasonably treated surgically; the feasibility of long-
term conservative surveillance of BRAF mutation-
positive PTMC initially presenting with low-risk clin-
ical features seems uncertain, making it reasonable at
this time to treat such thyroid cancer surgically, albeit
with limited surgical extentdthyroid lobectomy, for
example. In contrast, conservative management in the
form of non-surgical active surveillance is reasonable for
BRAF mutation-negative low-risk PTMC, which ac-
counts for the majority of patients with clinically low-
risk PTMC. Thus, more precise management of pa-
tients with low-risk PTMC can be achieved by including
the BRAF V600E mutation status in the prognostic risk
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